{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-21-000171","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.080983+00:00","generated_at":"2026-06-28T15:08:11.302190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II","bullets":["U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.","GAAP operating loss $19.1M vs. $8.8M YoY; non-GAAP operating loss $14.3M vs. $6.5M.","Cash $107.8M at Sept 30, down from $131.7M due to $15M milestone payment.","Initiated Phase II for extra-strength Jeuveau; first patient expected Q1 2022, completion 1H 2023.","Accounts purchasing Jeuveau increased by 500 to >6,500; loyalty program doubled to 240,000 registrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-21-000171","json":"https://secwatch.observer/filing/0001570562-21-000171.json","markdown":"https://secwatch.observer/filing/0001570562-21-000171.md","text":"https://secwatch.observer/filing/0001570562-21-000171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/0001570562-21-000171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/eols-20211102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:08:11.302190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}